1.17. Analysis.
Comparison 1 Anti‐leukaemic therapy plus alemtuzumab versus anti‐leukaemic therapy alone (anti‐leukaemic therapy identical in both groups; unconfounded), Outcome 17 Anaemia grade 3/4 ‐ overall analysis.
Comparison 1 Anti‐leukaemic therapy plus alemtuzumab versus anti‐leukaemic therapy alone (anti‐leukaemic therapy identical in both groups; unconfounded), Outcome 17 Anaemia grade 3/4 ‐ overall analysis.